A B S T R A C T Humoral factors released from platelets during pulmonary embolism may be the cause of several attendant cardiopulmonary abnormalities. This study examines the role of thromboxanes (Tx) after experimental embolism induced with 0.5 g/kg autologous clot in four groups of five dogs: (a) untreated embolized controls; (b) pretreatment with the Tx synthetase inhibitor, imidazole 25 mg/kg -h i.v., starting 30 min before embolization; (c) pretreatment with the cyclooxygenase inhibitor indomethacin, 5 mg/kg, 12 h per os and 1 mg/kg, 1 h i.v. before the experiment; (d) treatment with prostacyclin (PGI2) 100 qg/kg. min i.v. for 1 h, 1 h after embolization. Within 30 min, embolization led to increases of 6-keto-PGF,a, the stable hydrolysis product of PGI2, from 0.11±0.08 ng/ml (mean±SD) to 0.33±0.10 7g/ml (P < 0.005) and TxB2, the stable product of TxA2, from 0.10±0.04 qg/ml to 0.38±0.0611g/ml (P < 0.001). Increases were observed in total dead space (VD/VT) from 0.46±0.03 to 0.61±0.08 (P < 0.025, physiologic shunting (Qs/(T) from 16±4% to 38±9% (P < 0.01), pulmonary vascular resistance (PVR) from 2.27±0.59 mm Hg.min/liter to 9.21±1.90 mm Hg* min/liter (P < 0.005) and mean pulmonary arterial pressure from 14±6 mm Hg to 34±1 mm Hg (P < 0.001). Cardiac index (CI) fell from 139±11 ml/kg.min to 95±17 ml/kg.min in 4h (P < 0.025). Imidazole pretreatment prevented a rise of TxB2, but not 6-keto-PGFj,; indomethacin blocked both. Both agents maintained VD/VT at base line and limited increases in Qs/QT and PVR. CI was higher after imidazole pretreatment compared with controls (P < 0.025). < 0.025), QS/QT (P < 0.025) and PVR (P < 0.05) within 30 min. During PGI2 infusion, CI was higher than controls. Concentrations of TxB2 correlated with VD/VT, r = 0.79 and Qs/QT, r = 0.69 (P < 0.001).
A B S T R A C T Humoral factors released from platelets during pulmonary embolism may be the cause of several attendant cardiopulmonary abnormalities. This study examines the role of thromboxanes (Tx) after experimental embolism induced with 0.5 g/kg autologous clot in four groups of five dogs: (a) untreated embolized controls; (b) pretreatment with the Tx synthetase inhibitor, imidazole 25 mg/kg -h i.v., starting 30 min before embolization; (c) pretreatment with the cyclooxygenase inhibitor indomethacin, 5 mg/kg, 12 h per os and 1 mg/kg, 1 h i.v. before the experiment; (d) treatment with prostacyclin (PGI2) 100 qg/kg. min i.v. for 1 h, 1 h after embolization. Within 30 min, embolization led to increases of 6-keto-PGF,a, the stable hydrolysis product of PGI2, from 0.11±0.08 ng/ml (mean±SD) to 0.33±0.10 7g/ml (P < 0.005) and TxB2, the stable product of TxA2, from 0.10±0.04 qg/ml to 0.38±0.0611g/ml (P < 0.001). Increases were observed in total dead space (VD/VT) from 0.46±0.03 to 0.61±0.08 (P < 0.025, physiologic shunting (Qs/(T) from 16±4% to 38±9% (P < 0.01), pulmonary vascular resistance (PVR) from 2.27±0.59 mm Hg.min/liter to 9.21±1.90 mm Hg* min/liter (P < 0.005) and mean pulmonary arterial pressure from 14±6 mm Hg to 34±1 mm Hg (P < 0.001). Cardiac index (CI) fell from 139±11 ml/kg.min to 95±17 ml/kg.min in 4h (P < 0.025). Imidazole pretreatment prevented a rise of TxB2, but not 6-keto-PGFj,; indomethacin blocked both. Both agents maintained VD/VT at base line and limited increases in Qs/QT and PVR. CI was higher after imidazole pretreatment compared with controls (P < 0.025). Indomethacin led to intermediate levels of CI. PGI2 lowered TxB2 (P <0.025), VD/VT (P
INTRODUCTION
Pulmonary embolism produces cardiopulmonary dysfunction that may result directly from mechanical obstruction of the pulmonary vasculature as well as indirectly by humoral factors (1) . It is believed that platelet interaction with a clot leads to platelet release reaction, which may be responsible for several of the attendant cardiopulmonary abnormalities such as pulmonary hypertension and increase of venous admixture (2, 3) . Platelet aggregation is inhibited by prostacyclin (PGI2),' which is largely produced by the vascular wall (4), whereas thromboxane (Tx) A2, a potent proaggregator, is produced by platelets (5). The ratio of circulating PGI2:TxA2 is likely to be significant in controlling platelet-endothelial interaction (5) , and therefore, aggregation and release of vaso-and bronchoactive agents. The present study was designed to ' Abbreviations used in this paper: CI, cardiac index; CO Prostaglandin assay. TxB2 and 6-keto-PGFIa, the stable derivatives of TxA2 and PGI2, respectively, were measured by radioimmunoassay (7) (8) (9) . Arterial blood was collected in cooled plastic syringes containing heparin. The blood was immediately centrifuged at 1,500 g for 20 min at 4°C. Plasma was separated and stored at -20°C until testing.
Specific rabbit Tx and PG antisera were stored in 0. control-blank [3] The acceptable inhibitory range was between 15 and 85%. The lower limit permitted the minimum detectable amount of TxB2 and 6-keto-PGF1. to be 6 or 10 pg, respectively.
Studies were performed to assess the serologic specificities of the antisera used in the radioimmunoassays. In the TxB2 system 28 pg TxB2 inhibited homologous binding by 50%; PGD2, PGE2, 13,14-dihydro-15,keto-PGF2, PGF2a, and 6-keto-PGF1, crossreacted <1%. In the 6-keto-PGFI. system, 140 pg 6-keto-PGFI. inhibited homologous binding by 50%;
6-keto-PGE1 crossreacted 3% while PGD2, PGE2, 13,14-dihydro-15-keto-PGE2, PGFIa, PGF2a, and TxB2 crossreacted <1% .
Embolization. Autologous blood was clotted with thrombin 10 U/ml blood. The clot was cut into 3-to 5-mm cubes, washed with saline, and 0.5 g/kg embolized intravenously to the lungs. Previous experience with this preparation using '311-fibrinogen to label the clot has shown the disappearance rate of "'lI activity to range between 3.2 and 5.3%/h during the 4-h observation period (10) . Pulmonary angiograms at 4 h demonstrated peripheral emboli in all lobes.
Animals were divided into four groups of five dogs in each: (a) untreated embolized controls; (b) pretreatment with the thromboxane synthetase inhibitor, imidazole 25 Fig. 2 ) and VD/VT rose from 0.46±0.03 to 0.61±0.08 (P < 0.025, Fig. 3 ). Thereafter, Qs/QT and VD/VT decreased, and at 4 h were 28±8% and 0.57±0.04, respectively. There were no significant changes in the base-line MAP of 134 mm Hg and PAWP of 7 mm Hg through the 4-h period of observation (Table I) . For the first 1 h, CI was unchanged. Thereafter, it decreased and at 4 h was 60% of base line (P < 0.025, Fig. 4) .
Platelet counts decreased 30%, 30 min after embolization (P < 0.025) and then remained stable (Table   I ). There was an increase in 6-keto-PGFia, from 0.11±0.08 7g/ml to 0.33±0.01 vg/ml (P < 0.005, Fig.   5 ) and TxB2 from 0.10±0.04 qg/ml to 0.38±0.06 i7g/ ml (P < 0.001, Fig. 6 ). Both cyclooxygenase prostanoids then decreased, and at 4 h were 0.18±0.09 ,7g/ ml and 0.14±0.06 tg/ml, respectively.
Imidazole infusion blocked the production of TxA2. TxB2 levels did not increase with embolization, while rapidly restored Qs/OT to base line.
6-keto-PGFIa rose to values similar to untreated controls. In further contrast to controls, Os/QT rose transiently from 16±2% to 31±6% (P < 0.025) and then returned to base line (Fig. 2) ; VD/VT remained unchanged through the experiment (Fig. 3) trols (P < 0.05, Fig. 4 ). Platelets decreased after embolization in a manner similar to controls (P < 0.05, Table I ).
In indomethacin-pretreated dogs, the base-line value of 6-keto-PGFia was 0.008±0.001 qg/ml, which was Efbfdus 150 k iook much lower than that of other groups (P <0.001).
After embolization, the concentration did not change (Fig. 4) . TxB2 concentration was also lower than that of other groups (P < 0.005, Fig. 5 ). After embolization, levels of TxB2 rose from 0.014±0.003 tg/ml to 0.023±0.005 ng/ml (P < 0.05), which was still significantly below controls. Embolization led to an insignificant decrease of Pao2; after 3 h, Pao2 had fallen to 75±5 mm Hg (P < 0.025). Qs/QT and VD/VT were not significantly changed by embolization (Figs. 2, 3 ). The increase in MPAP was similar to controls. PVR rose; at 1 h it was significantly lower than controls and reached equivalency at 3 h. CI was well maintained within the first 2 h, but then decreased in the next 2 h to a value 79% of base line (Fig. 4) . Platelets decreased in the same fashion as controls. PGI2 infusion was started 1 h after embolization. The plasma concentration of 6-keto-PGFIa rose to 4.51±3.25 ng/ml at the end of the infusion period.
After cessation of PGI2, the concentration returned to base line in 30 min. After 30 min, PGI2 lowered TxB2 concentration (P < 0.005), reducing the value below control animals (P < 0.025). However, 30 min after cessation of PGI2, TxB2 levels rose above control (P < 0.05). PGI2 infusion reversed the fall in Pao2 and rise in Qs/QT (P < 0.025, Fig. 2 ). VD/VT also decreased 30 min after the start of PGI2 infusion (P < 0.025) to levels lower than control (P < 0.05). However, 30 min after cessation of PGI2 infusion, VD/VT rose (P < 0.025) concomitant with the increase of TxB2. Arterial and MPAP were also lowered during PGI2 (P < 0.05), as was PVR (P < 0.05). CI was maintained during the infusion (P < 0.05), but 30 min later dropped to values similar to controls. Platelet numbers were not restored by PGI2 infusion. VD/VT and TxB2 concentration in control and PGI2
groups correlated well (r = 0.79, P < 0.001, Fig. 7 ). The Qs/QT was also related to TxB2 (r = 0.69, P < 0.001). 30 min after embolization, the increase of TxB2 related to a decrease of platelets in control and PGI2 groups (r = -0.64, P < 0.001).
Ketoconazole given 30 min after embolization to three dogs, appeared to influence only VDp/VT. 2 h after embolus, VDp/VT was 22% (Table II) , while (1, 11, 12) . Present investigations show that emboli cause production of the antiaggregator and vasodilator PGI2, as well as the proaggregator and constrictor, TxA2. PGI2 is produced by vessel walls, while TxA2 is synthesized in platelets and perhaps lung parenchyma (4, 13, 14) . Our observation that the concentration of TxB2, the stable degradation product of TxA2 is temporally related to the fall in platelet count (r = -0.64) suggests that in this setting TxA2 may originate in platelets that have aggregated.
Inhibition of TxA2 synthesis with imidazole, but not the thrombocytopenia, indicates that aggregation after embolization is independent of TxA2. Induced thrombocytopenia or inhibition of platelet function by indomethacin has in the past been shown to modify the effects of microembolism (15, 16) . Present data suggest that TxA2, directly by smooth muscle constriction or indirectly by promoting release of smooth muscle constrictors such as platelet serotonin (5-hydroxytryptamine, 5-HT), is responsible for at least some of the cardiopulmonary abnormalities after experimental pulmonary embolism. Inhibition of TxA2 synthetase by pretreatment with imidazole and inhibition of cyclooxygenase by pretreatment with indomethacin (Figs. 5, 6 ) modified the rise in Qs/QT and prevented any increase in VD/VT (Figs. 2, 3) . The CI was better maintained along with lower PVR (Figs.  3, 4) .
Infusion of PGI2 led to decreased concentration of TxA2 and prompt reductions of QS/QT, VD/VT, MPAP, and PVR with maintenance of CI. These salutary cardiopulmonary effects of PGI2 have been reported and have been related to a direct action on pulmonary arterial smooth muscle causing vasodilation as well as enhanced fibrinolytic activity (10, 17) . The very prompt reduction in (s/0T and VD/VT excludes PGI2-induced clot lysis as the mechanism of action. A selective PGI2 effect of vaso-and bronchodilation has been suggested by our finding that a PGE1 infusion will reduce MPAP to levels lower than PGI2, but surprisingly, will worsen Qs/QT and VD/VT (18) . Other actions of PGI2 are to antagonize the vaso-and broncho-constriction induced by 5-HT infusion (19) and to lower plasma 5-HT levels after experimental pulmonary embolization (20) . Since PGI2 modifies plasma and platelet 5-HT transport, it is possible that PGI2 not only acts directly to relax vascular and bronchial smooth muscle, but also acts indirectly in inhibiting the synthesis and/or release of the platelet agents, TxA2 and 5-HT, which mediate smooth muscle constriction. The present data support the postulate that release of platelet secretions can be modified by PGI2, and that this event is related to improvement in cardiopulmonary function.
Obstruction of the pulmonary vasculature by emboli leads to ventilation without perfusion. That this rise in VD/VT could be prevented or reversed with inhibitors of TxA2 synthesis was unexpected since this functional abnormality has usually been considered to be a simple mechanical event. It is likely that inhibition of TxA2 secretion by platelets layering onto the embolus prevents intense constriction distal to the clot. As long as there is some perfusion through these embolized segments, the measured VD/VT will appear unchanged (21) . This is related to the method of measurement, using the very soluble gas CO2, which is sensitive only to very high ventilation/perfusion ratios.
The PGI2 group illustrates the close association of TxA2 and VD/VT. When PGI2 with t½ of 2-3 min was stopped, TxA2 concentrations rapidly rose along with VD/VT (Figs. 3, 6 ). As TxA2 decreased, so did VD/VT. The excellent correlation of TxB2 with VD/VT in control and PGI2 studies strongly suggests a causal relationship (Fig. 7) . The ability of ketoconazole given after embolization to reduce TxB2 and VDP/VT adds further support to this thesis.
The fact that MPAP was little altered and PVR only moderately reduced in the treatment groups after embolization shows that significant reductions in the cross-sectional area of the pulmonary vascular bed still existed despite normal VD/VT. It is likely that other vasoactive platelet secretions are involved in the control of PVR. Serotonin is important. Administration of the antagonist cyproheptadine before embolization, using the same preparation as reported in this study prevented any rise in PVR (20) .
There are a number of possible causes of the decline in CI after pulmonary embolism. Most noteworthy is right ventricular failure secondary to pulmonary hypertension. In addition, TxA2 has been reported by our laboratory to be associated with a circulating agent that causes reduction in cardiac output and cardiac contractility (22, 23 (Fig. 2) , and also that ketoconazole was without beneficial effect. Further, PGI2-infused animals maintained a low (s/(T even after cessation of PGI2, a time when TxA2 concentrations rose transiently. Other bronchoconstrictors, particularly serotonin, may also participate in producing the hypoxemia of embolization (24) . An infusion of 5-HT will lower arterial oxygen tension that can be restored by a simultaneous infusion of PGI2 (19) . In this setting, PGI2 may be acting both as a bronchodilator as well as a promotor of rapid 5-HT clearance by platelets (20) . Pretreatment with imidazole and indomethacin inhibits TxA2 synthesis (Fig. 6) , and although these drugs did not inhibit platelet sequestration and loss, it is possible that they modified platelet 5-HT release accounting for the attenuated rise in Qs/QT.
Posttreatment with ketoconazole did not alter Qs/QT At this time, after platelet sequestration, it is unlikely that the drug influenced 5-HT release. These results suggest that many of the cardiopulmonary effects of embolism are related to platelet secretions. However, extrapolation of these data to the clinical setting must be done with caution. Our experimental use of fresh clot divided into small fragments permitted embolization of peripheral vessels. This varies from the usual findings in patients where older and larger clot fragments with less surface area for platelet activation are the rule. It is possible that patients suffer quantitatively fewer humorally mediated effects of embolism than those noted in this study.
Cardiopulmonary function has also been shown to be altered in other states where platelets are entrapped in the lungs such as microembolism, sepsis, and abdominal aortic aneurysm repair (1, 11, 14, 15, 25, 26) . In addition to platelet synthesis of TxA2, the observation that lung parenchyma can be stimulated by antigen antibody reaction to release thromboxanes (27) indicates that pulmonary metabolic events may also influence cardiopulmonary function.
